ROR1 and lymphoma: In various lymphoid cancers, Zilovertamab Vedotin, an anti-ROR1 antibody coupled to the microtubule inhibitor Auristatin E, could achieve partial response in the subgroup of patients with mantle cell lymphoma and diffuse large cell B-cell lymphoma [187].